Cell Therapy Expert Dr. Amit Patel Joins Regen BioPharma Scientific Advisory Board

SAN DIEGO, CA--(Marketwired - October 15, 2014) - Regen BioPharma Inc. (OTCBB: RGBP) announced today the appointment of Dr. Amit Patel to the company’s Scientific Advisory Board (SAB). Dr. Patel is Director of Clinical Regenerative Medicine and Tissue Engineering at the University of Utah and has been involved in over 17 FDA trials in the area of cellular therapy. Dr. Patel currently holds more than $7 million in research grants for basic and clinical research in the area of regenerative medicine.

“It is my honor to continue working with Dr. Patel. At our previous work in Medistem, Dr. Patel was critical in initiation and execution of clinical trials, which led to the eventual sale of the company to Intrexon, a NYSE traded company,” said Dr. Thomas Ichim, Ph.D., Chief Scientific Officer of Regen BioPharma. “Dr. Patel’s expertise in the area of adipose stem cells will greatly add to our HemaXellerate program, which utilizes adipose tissue as starting material. Additionally, his overall familiarity with commercialization of cellular therapy products will accelerate our ongoing efforts in the development of the dCellVax breast cancer vaccine.”

Dr. Patel has a Masters of Sciences in Immunology, studied medicine at the Case Western Reserve University, and was a surgical intern, resident and fellow at Baylor University. He was a faculty member at University of Pittsburgh and currently is a faculty member at the University of Utah. In 2002, he led a “breakthrough” study demonstrating that stem cell transplantation could treat congestive heart failure, being the first doctor to inject stem cells into the human heart. Notable patients of his include Hawaiian singer Don Ho; Ho credited Patel’s 2005 procedure on him with saving his life and allowing him to return to performing after being forced into retirement for health reasons. Dr. Patel holds numerous industry and governmental grants including from the National Institutes of Health (NIH) and the Department of Defense.

“My involvement with Regen BioPharma dates back to the inception of the HemaXellerate program, where I was senior author on the peer-reviewed publication describing its rationale (publication is available at http://www.translational-medicine.com/content/pdf/1479-5876-10-231.pdf),” said Dr. Amit Patel. “I am very enthusiastic to formally join the team and to help in the process of bringing these new medicines to patients.”

About Regen BioPharma Inc.:
Regen BioPharma Inc. (OTCBB: RGBP) is a majority owned subsidiary of Bio-Matrix Scientific Group, Inc. (PINKSHEETS: BMSN). Regen is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials.

Currently the Company is focused on developing treatments for Aplastic Anemia and a gene silencing therapy for treating cancer. For more information refer to the company’s website http://www.regenbiopharma.com/

Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.